Nab-Paclitaxel (paclitaxel protein-bound particles for injectable suspension)
Abraxis BioScience / Celgene (brand: Abraxane); generics available including Ciplo formulation · Taxane / Microtubule Stabilizer (Albumin-Bound Formulation)
What is Nab-Paclitaxel? Nab-paclitaxel (paclitaxel protein-bound) is an albumin-bound formulation of paclitaxel that does not require Cremophor EL as a solvent, avoiding many of the hypersensitivity reactions and premedication requirements associated with conventional paclitaxel. The brand Abraxane is FDA-approved for breast cancer, NSCLC, and pancreatic cancer.
About Nab-Paclitaxel
| Brand Name | Nab-Paclitaxel |
| Generic / INN | paclitaxel protein-bound particles for injectable suspension |
| Drug Class | Taxane / Microtubule Stabilizer (Albumin-Bound Formulation) |
| Manufacturer | Abraxis BioScience / Celgene (brand: Abraxane); generics available including Ciplo formulation |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2005 |
FDA-Approved Uses for Nab-Paclitaxel
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Metastatic breast cancer — after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy
- Non-small cell lung cancer (NSCLC) — first-line with carboplatin
- Metastatic adenocarcinoma of the pancreas — first-line with gemcitabine
How Does Nab-Paclitaxel Work?
Nab-paclitaxel consists of paclitaxel bound to albumin nanoparticles (~130 nm). Albumin-bound paclitaxel leverages albumin transport pathways (including SPARC-mediated and gp60-mediated transcytosis) to deliver paclitaxel to tumor tissue. Once in the tumor microenvironment, paclitaxel binds beta-tubulin, stabilizing microtubules and blocking mitosis.
Dosage & Administration
Dosing depends on indication and combination regimen, determined by the oncologist based on BSA. Nab-paclitaxel does NOT require premedication for hypersensitivity prophylaxis that conventional Cremophor-based paclitaxel requires, though institutional protocols vary.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
Myelosuppression (neutropenia is dose-limiting). Sensory neuropathy — can be severe and cumulative. Do NOT substitute nab-paclitaxel for other paclitaxel formulations on a mg-per-mg basis — they are NOT interchangeable. Hepatic impairment requires dose adjustment. Embryo-fetal toxicity.
- Severe neutropenia
- Severe sensory neuropathy
- Pneumonitis
- NOT interchangeable with other paclitaxel formulations
- Embryo-fetal toxicity
Common Side Effects
- Peripheral neuropathy
- Neutropenia
- Alopecia
- Fatigue
- Nausea
- Diarrhea
- Myalgia/arthralgia
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Intact vials: store at room temperature 20°C to 25°C (68°F to 77°F). Reconstituted suspension: refrigerate 2°C to 8°C (36°F to 46°F); use within 8 hours.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Nab-Paclitaxel is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Nab-Paclitaxel. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Nab-Paclitaxel
Nab-paclitaxel (brand name Abraxane) is an albumin-bound formulation of paclitaxel that avoids the solvent Cremophor EL used in conventional paclitaxel. It is approved for metastatic breast cancer, non-small cell lung cancer (with carboplatin), and pancreatic cancer (with gemcitabine).
No. While both contain paclitaxel as the active ingredient, nab-paclitaxel (Abraxane) and conventional paclitaxel are NOT interchangeable. They have different dosing, administration times, premedication requirements, and toxicity profiles. Substituting them on a mg-per-mg basis can cause serious harm.
The most common serious side effects are peripheral neuropathy (numbness/tingling, which can be cumulative) and neutropenia (low white blood cell count). Both may require dose reduction.
Nab-paclitaxel (Abraxane) is covered by Medicare Part B and most commercial insurance for approved indications with prior authorization. Generic versions may have different formulary status.
Related Medications & Conditions
Related Medications
Paclitaxel (conventional) · Gemcitabine · Carboplatin · Docetaxel
Related Conditions
Metastatic breast cancer · Non-small cell lung cancer · Pancreatic cancer